Clinical Trial: Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Non Small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: Phase II Feasibility Study of Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC
Brief Summary:
This study is to determine if a fecal microbiota transplant (FMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
Read more